33.27 USD
+0.64 (+1.96%)
At close: Feb 2, 2026
33.27 USD
0 (0%)
After Hours: 2/2/2026, 8:10:48 PM
Taking everything into account, GMAB scores 7 out of 10 in our fundamental rating. GMAB was compared to 524 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make GMAB a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- GMAB had positive earnings in the past year.
- GMAB had a positive operating cash flow in the past year.
- Each year in the past 5 years GMAB has been profitable.
- GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- GMAB has a better Return On Assets (21.10%) than 97.33% of its industry peers.
- The Return On Equity of GMAB (25.76%) is better than 97.14% of its industry peers.
- With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
- GMAB had an Average Return On Invested Capital over the past 3 years of 15.20%. This is below the industry average of 18.09%.
- The last Return On Invested Capital (17.11%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- GMAB has a better Profit Margin (41.35%) than 97.33% of its industry peers.
- In the last couple of years the Profit Margin of GMAB has declined.
- With an excellent Operating Margin value of 36.85%, GMAB belongs to the best of the industry, outperforming 97.90% of the companies in the same industry.
- In the last couple of years the Operating Margin of GMAB has declined.
- With an excellent Gross Margin value of 94.27%, GMAB belongs to the best of the industry, outperforming 94.85% of the companies in the same industry.
- GMAB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
- The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
- GMAB has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 12.07 indicates that GMAB is not in any danger for bankruptcy at the moment.
- The Altman-Z score of GMAB (12.07) is better than 84.54% of its industry peers.
- GMAB has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
- GMAB has a better Debt to FCF ratio (0.12) than 95.80% of its industry peers.
- A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.02, GMAB is in line with its industry, outperforming 43.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 12.07 |
ROIC/WACC2.34
WACC7.32%
2.3 Liquidity
- A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
- With a decent Current ratio value of 6.03, GMAB is doing good in the industry, outperforming 62.79% of the companies in the same industry.
- GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 6.01, GMAB is in the better half of the industry, outperforming 63.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 125.90% over the past year.
- Measured over the past years, GMAB shows a very strong growth in Earnings Per Share. The EPS has been growing by 28.38% on average per year.
- GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.66%.
- The Revenue has been growing by 31.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
- GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.30% yearly.
- GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.38% yearly.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 14.10, which indicates a correct valuation of GMAB.
- Based on the Price/Earnings ratio, GMAB is valued cheaper than 96.95% of the companies in the same industry.
- GMAB is valuated cheaply when we compare the Price/Earnings ratio to 28.41, which is the current average of the S&P500 Index.
- GMAB is valuated rather expensively with a Price/Forward Earnings ratio of 19.54.
- 93.89% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of GMAB to the average of the S&P500 Index (25.64), we can say GMAB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.1 | ||
| Fwd PE | 19.54 |
4.2 Price Multiples
- GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.76% of the companies in the same industry.
- 96.18% of the companies in the same industry are more expensive than GMAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.03 | ||
| EV/EBITDA | 10.95 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GMAB does not grow enough to justify the current Price/Earnings ratio.
- GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.19
PEG (5Y)0.5
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
5. Dividend
5.1 Amount
- No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
33.27
+0.64 (+1.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.49B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target28.4 (-14.64%)
Short Float %1.88%
Short Ratio6.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.44%
EPS NQ rev (3m)0.39%
EPS NY rev (1m)3.51%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.1 | ||
| Fwd PE | 19.54 | ||
| P/S | 5.72 | ||
| P/FCF | 17.03 | ||
| P/OCF | 16.08 | ||
| P/B | 3.56 | ||
| P/tB | 5.62 | ||
| EV/EBITDA | 10.95 |
EPS(TTM)2.36
EY7.09%
EPS(NY)1.7
Fwd EY5.12%
FCF(TTM)1.95
FCFY5.87%
OCF(TTM)2.07
OCFY6.22%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)2.19
PEG (5Y)0.5
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 12.07 |
F-Score7
WACC7.32%
ROIC/WACC2.34
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 14.1 and the Price/Book (PB) ratio is 3.56.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.